Patents by Inventor Wenqing Yao

Wenqing Yao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 12083124
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: January 26, 2023
    Date of Patent: September 10, 2024
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
  • Imidazotriazines and imidazopyrimidines as kinase inhibitors
    Patent number: 12084449
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: September 10, 2024
    Assignees: INCYTE HOLDINGS CORPORATION, INCYTE CORPORATION
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • Imidazole and triazole KRAS inhibitors
    Patent number: 12077539
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: September 3, 2024
    Assignee: Incyte Corporation
    Inventors: Chao Qi, Xiaozhao Wang, Wenqing Yao
  • PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20240287059
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: September 8, 2023
    Publication date: August 29, 2024
    Inventors: Oleg Vechorkin, Jun Pan, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20240287086
    Abstract: The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: December 19, 2023
    Publication date: August 29, 2024
    Inventors: Matthew S. McCammant, Evan Styduhar, Oleg Vechorkin, Robert Swyka, Wenqing Yao
  • CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy
    Patent number: 12060433
    Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: August 13, 2024
    Assignee: Incyte Corporation
    Inventors: Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane, Hui Wang, Yingnan Chen, Xiaozhao Wang, Peter Niels Carlsen, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu, Taisheng Huang
  • SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
    Publication number: 20240246974
    Abstract: The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: October 20, 2023
    Publication date: July 25, 2024
    Inventors: Liangxing Wu, Colin Zhang, Chunhong He, Liang Lu, Wenqing Yao
  • Hetero-tricyclic compounds as inhibitors of KRAS
    Patent number: 12030883
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: September 20, 2022
    Date of Patent: July 9, 2024
    Assignee: Incyte Corporation
    Inventors: Peter Carlsen, Ken Mukai, Haolin Yin, Xiaozhao Wang, Wenqing Yao, Wenyu Zhu
  • Imidazopyridazine and imidazopyridine compounds and uses thereof
    Patent number: 12030889
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: July 9, 2024
    Assignee: Incyte Corporation
    Inventors: Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
  • Pyrazoloquinoline KRAS inhibitors
    Patent number: 12030884
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: July 9, 2024
    Assignee: Incyte Corporation
    Inventors: Wenyu Zhu, Xiaozhao Wang, Wenqing Yao
  • HETEROCYCLYLAMINES AS PI3K INHIBITORS
    Publication number: 20240216377
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: October 3, 2023
    Publication date: July 4, 2024
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks, Brent Douty, Chunhong He
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 12012409
    Abstract: The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: June 18, 2024
    Assignee: Incyte Corporation
    Inventors: Jeremy Roach, Artem Shvartsbart, Michael Witten, Wenqing Yao
  • Vinyl imidazole compounds as inhibitors of KRAS
    Patent number: 11999752
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: June 4, 2024
    Assignee: Incyte Corporation
    Inventors: Peter Carlsen, Xiaozhao Wang, Alexander Sokolsky, Pei Gan, Rocco Policarpo, Wenqing Yao
  • Fused pyrazine derivatives as A2A / A2B inhibitors
    Patent number: 11999740
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: June 4, 2024
    Assignee: Incyte Corporation
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu
  • BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20240174664
    Abstract: The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: November 1, 2023
    Publication date: May 30, 2024
    Inventors: Yingda Ye, Zhenwu Li, Ding-Quan Qian, Sarah Winterton, Kaijiong Xiao, Liangxing Wu, Wenqing Yao, Joshua Hummel, Meizhong Xu, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
  • CARBOXAMIDE COMPOUNDS AND USES THEREOF
    Publication number: 20240150326
    Abstract: Disclosed are compounds of Formula (I?) methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: June 21, 2023
    Publication date: May 9, 2024
    Inventors: Oleg Vechorkin, Jun Pan, Alexander Sokolsky, Evan Styduhar, Qinda Ye, Wenqing Yao
  • TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS
    Publication number: 20240150354
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: August 24, 2023
    Publication date: May 9, 2024
    Inventors: Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Spirocyclic lactams as JAK2 V617F inhibitors
    Patent number: 11958861
    Abstract: The present application provides spirocyclic lactam compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: April 16, 2024
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Charles Cole, Nikoo Falahatpisheh, Kai Liu, Lixin Shao, Darius Vrubliauskas, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Tricyclic heterocycles as FGFR inhibitors
    Patent number: 11939331
    Abstract: The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: March 26, 2024
    Assignee: Incyte Corporation
    Inventors: Xin Li, Evan Styduhar, Robert Swyka, Oleg Vechorkin, Wenqing Yao
  • Quinoline compounds as inhibitors of KRAS
    Patent number: 11939328
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: March 26, 2024
    Assignee: Incyte Corporation
    Inventors: Qinda Ye, Matthew McCammant, Artem Shvartsbart, Wenyu Zhu, Bin Hu, Chao Qi, Xiaozhao Wang, Wenqing Yao, Alexander Sokolsky